Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - other diseases
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Biotest opens new plasma collection centre in Vermil...

28.09.2016, News

Biotest opens new plasma collection centre in Vermillion, South Dakota, USA - 13 plasma collection centres in Europe - 21 in the US to ensure long-term plasma supply Dreieich, 28 September ... [More]

Biotest increases EBIT significantly

11.08.2016, News

Biotest increases EBIT significantly - Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million - Increase of revenue by 6.4% to EUR 306 million - Operating Cash flow increased to EUR ... [More]

Altered Tax Assessments for 2005 - 2008

03.08.2016, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered Tax Assessments for 2005 - 2008 Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office ... [More]

Biotest AG opens fifth plasma collection centre in Hung...

29.07.2016, News

Biotest AG opens fifth plasma collection centre in Hungary - Thirteen plasma collection centres in Europe and - Twenty in the US to ensure long-term plasma supply Dreieich, 29 July 2016. ... [More]

Biotest opens new plasma collection centre in Clemson, ...

27.07.2016, News

Biotest opens new plasma collection centre in Clemson, South Carolina, USA - 12 plasma collection centres in Europe - 20 in the US to ensure long-term plasma supply Dreieich, 27 July 2016. ... [More]

Release according to Article 26, Section 1 of the WpHG ...

21.07.2016, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Former Biotest employee sentenced

14.07.2016, News

Former Biotest employee sentenced Dreieich, 14 July 2016. Today, the Landgericht Darmstadt (District Court Darmstadt, Germany) sentenced a former Biotest representative for Russia to imprisonment ... [More]

Biotest opens new plasma collection centre in Brookings...

24.05.2016, News

Biotest opens new plasma collection centre in Brookings, South Dakota, USA - 12 plasma collection centres in Europe - 19 in the US to ensure long-term plasma supply Dreieich, 24 May 2016. ... [More]

Pentaglobin(R) showed a significant survival benefit i...

23.05.2016, News

Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria - Additional therapy with Pentaglobin(R) significantly reduced the relative ... [More]

Annual general meeting approves payout of dividend

12.05.2016, News

Biotest AG: Annual general meeting approves payout of dividend - Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per preference share Dreieich/ Frankfurt a. M., 12 May 2016. At ... [More]

Biotest increases EBIT significantly in the first quart...

12.05.2016, News

Biotest increases EBIT significantly in the first quarter 2016 - Increased Guidance confirmed - Good start of cooperation with Kedrion - Dividend proposed Dreieich, 12 May 2016. In the ... [More]

Biotest AG opens fourth plasma collection centre in Hun...

07.04.2016, News

Biotest AG opens fourth plasma collection centre in Hungary - Twelve plasma collection centres in Europe and - Eighteen in the US to ensure long-term plasma supply Dreieich, 7 April 2016. ... [More]

Increase of guidance 2016 by more than 10%

23.03.2016, News

Increase of guidance 2016 by more than 10% - Positive operating cash flow of EUR 38.1 million in 2015 - Equity ratio of 42.8% Dreieich, 23 March 2016. 2016. In the 2015 financial year, the ... [More]

IgM Concentrate: Remarkable relative reduction in morta...

16.03.2016, News

IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients - Favourable new data of phase II trial with IgM Concentrate in patients with severe ... [More]

Biotest exceeds EBIT guidance for 4th quarter 2015

11.02.2016, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest exceeds EBIT guidance for 4th quarter 2015 Dreieich, 11. February 2016. According to preliminary and unaudited figures, ... [More]

Correction of the Ad hoc announcement dated February 11...

11.02.2016, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the ... [More]

Biotest enters into an exclusive cooperation agreement ...

19.01.2016, News

Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam(R) in the U.S. - Kedrion Biopharma takes over the distribution of Bivigam(R) in the ... [More]

Kreissparkasse Biberach continues to be major sharehold...

14.01.2016, News

Kreissparkasse Biberach continues to be major shareholder of Biotest Dreieich, 14. January 2016. "Biotest has today published a notification of existing voting rights, pursuant to section 41, ... [More]

Pentaglobin(R) showed encouraging results in the treatm...

14.01.2016, News

Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation - In lung transplantation early new donor specific antibodies (DSA) are ... [More]

Release according to Article 26, Section 1 of the WpHG ...

14.01.2016, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]